Every Afirma Genomic Sequencing Classifier (GSC) test performed includes whole-transcriptome-derived analysis covering over 21,000 genes and over 98% of the reference sequence exome.²³ This data fuels Afirma GRID and can be made available upon request for use on a research-use-only basis for thyroid nodules that are deemed suspicious for cancer by the Afirma GSC or are reported as Bethesda V or VI by cytopathology.

Learn more about Afirma’s whole transcriptome approach here: https://www.mdpi.com/2075-4426/13/1/24